- Home
- TC vs RANI Comparison
TC vs RANI Comparison
Compare TC & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TC
- RANI
- Stock Information
- Founded
- TC 2010
- RANI 2012
- Country
- TC China
- RANI United States
- Employees
- TC N/A
- RANI N/A
- Industry
- TC Business Services
- RANI Medicinal Chemicals and Botanical Products
- Sector
- TC Consumer Discretionary
- RANI Health Care
- Exchange
- TC Nasdaq
- RANI Nasdaq
- Market Cap
- TC 25.0M
- RANI 24.2M
- IPO Year
- TC 2018
- RANI 2021
- Fundamental
- Price
- TC $18.56
- RANI $2.26
- Analyst Decision
- TC
- RANI Strong Buy
- Analyst Count
- TC 0
- RANI 6
- Target Price
- TC N/A
- RANI $8.67
- AVG Volume (30 Days)
- TC 14.0K
- RANI 52.8M
- Earning Date
- TC 12-16-2025
- RANI 11-07-2025
- Dividend Yield
- TC N/A
- RANI N/A
- EPS Growth
- TC N/A
- RANI N/A
- EPS
- TC N/A
- RANI N/A
- Revenue
- TC $5,115,721.00
- RANI $1,200,000.00
- Revenue This Year
- TC N/A
- RANI N/A
- Revenue Next Year
- TC N/A
- RANI N/A
- P/E Ratio
- TC N/A
- RANI N/A
- Revenue Growth
- TC N/A
- RANI N/A
- 52 Week Low
- TC $9.20
- RANI $0.39
- 52 Week High
- TC $39.00
- RANI $3.87
- Technical
- Relative Strength Index (RSI)
- TC 70.64
- RANI 61.96
- Support Level
- TC $16.50
- RANI $1.42
- Resistance Level
- TC $18.00
- RANI $3.87
- Average True Range (ATR)
- TC 1.29
- RANI 0.62
- MACD
- TC 0.11
- RANI 0.03
- Stochastic Oscillator
- TC 74.60
- RANI 34.29
About TC TuanChe Limited
Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.